Statins remain a mainstay in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). CONCLUSION AND RELEVANCE Statin use increased substantially in the last decade among US adults, although the uptake was suboptimal in high-risk groups. While total and OOP expenditures associated with statins decreased, further substitution of brand-name to generic statins may yield more savings.
effectiveness has been established in several subgroups, 7, 8 these results are as sensitive to the cost of statins as they are to users' risk level. While the recent introduction of generic statins has led to a decrease in the cost of statins, to our knowledge, trends of the intensity or expenditures on statins have not been robustly examined.
In this study, we analyzed the nationally representative Medical Expenditure Panel Survey (MEPS) data from 2002 to 2013 to delineate trends in statin use and costs. These results could have important insights for guidelines and public health discussions aimed at improving the efficiency and costeffectiveness of statin use in appropriate primary and secondary prevention populations.
Methods

Study Design and Population
We performed a 12-year retrospective, longitudinal cohort study of US adults 40 years and older using the 2002-2013 MEPS database. The database is sponsored by the Agency for Healthcare Research and Quality and is a national survey of individuals and families, clinicians, and employers for medical conditions and health care resource use and costs. Each year, the MEPS Household Components' sample is drawn from respondents of the previous year's National Health Interview Survey. It has an overlapping panel design, with each panel composed of randomly sampled, noninstitutionalized US civilians. Participants are interviewed every 6 months over 30 months and their responses are reported annually to provide nationally representative estimates of sociodemographic characteristics, medical conditions, and health care use and costs. 9 Interviews are conducted over the telephone, and further information is obtained from physicians, hospitals, and pharmacies to supply additional information on health care use and cost data. After data collection, Agency for Healthcare Research and Quality researchers assign person-weights and variance estimation stratum to reflect survey nonresponse and population totals from the participants surveyed. 10 Because the MEPS consists of publicly available, deidentified data files, this current study was exempted from institutional review board approval, per the US Department of Health and Human Services guidelines. Written consent was obtained from participants to be contacted for interviews and to contact their clinicians and pharmacies. We merged the MEPS Household Components' full-year consolidated, medical conditions, and prescribed medicines files for each year from 2002 to 2013 to create annual files with sociodemographic characteristics, medical conditions, and medication use and expenditures. For ease of analysis and reporting, we pooled data into 2-year cycles and adjusted the person-level weight accordingly to reflect the mean annual population size and medication use and expenditures of the 2 years in each cycle. Individuals included in our analysis were 40 years of age and older at the time of the survey, had a body mass index (calculated as weight in kilograms divided by height in meters squared) of 18.5 or more (underweight individuals generally represent a sicker population), 11 and with a final survey person-weight greater than 0 to be representative of the national population at the time of the survey (eFigure 1 in the Supplement). Our study population was stratified into 2 ASCVD risk groups 1,2 : participants with known ASCVD included (1) those with coronary heart disease (CHD) and (2) those with stroke and/or peripheral arterial disease and participants without known ASCVD substratified into (1) those with diabetes and (2) those with dyslipidemia and without diabetes. Participants were classified into these groups if they had an International Statistical Classification of Diseases, Ninth Revision, Clinical Modification diagnosis of the condition (eTable 1 in the Supplement) and/or self-reported history of the diagnosis.
Statin Use and Expenditures
During the household interview, MEPS respondents were asked to supply the name of any prescribed medicine they or their family members purchased or otherwise obtained in the reference period. The interviewers entered verbatim the names of the prescription and other information as reported by the respondents, 12 who were also asked for permission to obtain payment data from pharmacies. With written permission from participants, pharmacies were contacted to obtain information on the date filled, national drug code, and medication medication information was then included in the MEPS Prescribed Medicine Files and linked to the Multum Lexicon database by Agency for Healthcare Research and Quality researchers, 13 which gives the class of drug. In this study, the Multum code 173 for 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was classified as statins. Because all lipidlowering combinations (Multum drug code 317) surveyed in MEPS contained an 3-hydroxy-3-methylglutaryl coenzyme A agent, we included them in the medications we identified as statins. For each year, we used the variable specifying the drug names to identify the major types of statins. We also used drug names to classify statins as brand name or generic. The strength of each prescribed medicine was used to generate the dose intensity of statin used; atorvastatin, 40 to 80 mg, and rosuvastatin, 20 to 40 mg, daily were classified as high-intensity statins, while all others were classified as moderate-to-low intensity.
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For each drug prescribed, the exact dollar amount paid was reported, as well as the source of payment, which included OOP (individual or family) or specific insurance coverage. Using these variables, we calculated drug-specific expenditures (overall expenditure and OOP). All expenditures were adjusted using the gross domestic product deflator to adjust annual expenditures from 2002 to 2013 to constant 2013 US dollars.
Covariates
We considered age, sex, race/ethnicity, family income, cardiovascular disease modifiable risk factors, and Charlson Comorbidity Index (CCI) score as factors that affect the time trends in statin use and expenditure and therefore were treated as covariates in our analyses. Participants' age as of the last day of the survey year were grouped into 3 categories: 40 to 64, 65 to 74, and 75 years and older. We had 5 categories of race and ethnicity: non-Hispanic white, non-Hispanic black, Hispanic, Asian, and other (American Indian, Alaska Native, and those who reported multiple races/ethnicities) categories. There were 5 categories of family income level as a proportion of the federal poverty level (FPL): poor (<100% of FPL), near poor (100%-<125% of FPL), low income (125%-<200% of FPL), middle income (200%-<400% of FPL), and high income (≥400% of FPL). We estimated participants' comorbidity burden using the Grouped CCI (GCCI), which has been described extensively elsewhere.
14,15 For our analysis, however, we modified the GCCI by excluding acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, and diabetes from our estimating GCCI score to avoid collinearity in our regression analyses. There were 3 categories for GCCI: 0, no comorbidity; 1, 1 long-term condition; and 2, 2 or more long-term conditions present other than CVD and/or diabetes. Hypertension, diabetes, and hyperlipidemia were determined using International Statistical Classification of Diseases, Ninth Revision, Clinical Modification diagnosis or self-report (eTable 1 in the Supplement).
Statistical Analysis
All analyses were conducted using Stata version 14 (StataCorp). Using the final person-weight and variance estimations (person sampling units and stratum), we accounted for the complex sampling design of the MEPS in all analyses to estimate nationally representative totals, means, and rates for persons in the civilian noninstitutionalized population. We applied the final person-weight adjusted for the 2-year cycles to the data and we used the svy: proportion command in Stata to estimate the proportion of the population using any, highintensity, generic, and brand-name statin per cycle; the svy:
total command to estimate the total number of persons reporting statin use, the total number of prescriptions, and the total expenditures; and the svy: mean command to estimate the average expenditures on any statin. Our trend analysis over the 12-year period was done using weighted linear regression models with estimated means or proportions as outcome variables and survey cycle as predictor. We determined the predictors of statin use using 3 different logistic regression models of statin use (yes vs no) on possible predictors. We performed a univariate logistic regression first, followed by model 1, which included the univariate predictors, and adjusted for age, sex, and race/ethnicity. Model 2 was a multivariate logistic regression consisting of all the predictor variables. We reported odd ratios (ORs) of statin use comparing other cycles with 2002-2003, the referent cycle. In all analyses, 95% CIs were reported, and 2-sided P < .05 was considered statistically significant. 
Results
Overall
Trends in Statin Use
The estimates of statin use (%) in the general adult population and in different risk groups are shown in Figure 1 . 
Distribution of Branded and Generic Statins
In [2002] [2003] 19 .9 million adults used brand-name statins, accounting for 91.6% of all statin prescriptions (n = 126 million). By 2012-2013, brand-name statins were only used by 18.2% of users (7.8 million adults; 44.4 million prescriptions), while 31.4 million adults were using generic statins (177 million prescriptions). A similar pattern was observed across all subgroups (eFigure 2 in the Supplement). Among available statins, atorvastatin remained the most commonly prescribed through 2006-2007, after which it was surpassed by simvastatin. In 2012-2013, simvastatin (41.4%) and atorvastatin (28.3%) were the most commonly used statins, followed by pravastatin (16.2%), rosuvastatin (11.2%), and lovastatin (7.0%) (eFigure 3 in the Supplement).
Predictors of Statin Use
The likelihood of any statin use in the general US population increased with calendar year (expressed as 2-year cycles) ( Table 3) . In a multivariable-adjusted analysis, compared with those aged 40 to 64 years, adults aged 65 to 74 years and adults aged 74 years or older were more likely to report 2012-2013 2002-2003 2004-2005 2006-2007 2008-2009 2010-2011 Non-ASCVD adults with dyslipidemia without diabetes a GCCI was modified for this study by excluding any cardiovascular disease or diabetes from the comorbidity index computation. 
Trends in Statin Expenditure
Discussion
Our study provides detailed insights into trends in use, disparities in uptake, and costs associated with statin use between 2002 and 2013. We observed a significant increase in statin use among the US general population; however, the observed uptake among individuals with established ASCVD-a group that derives the greatest benefit from statins-was suboptimal. Furthermore, the use of high-intensity statins among patients with established ASCVD was particularly low. Our study also found that despite improvement in statin use, significant inequities persist in various subgroups such as women, racial/ethnic minorities, and the uninsured. Last, while significant reductions in costs were associated with increased use of generic statins, branded statins continued to account for a larger portion of overall and OOP costs. Overall, statin use increased by 79% among the US adult population, rising from 17.9% to 27.8% from 2002-2003 to 2012-2013 While high-intensity statins improve outcomes in highrisk populations and their use is a class 1A recommendation, we noted significant underuse of high-intensity statins among selected population groups. In those with established ASCVD, high-intensity statins were used by only 21.5% patients in 2002-2003, rising to 28.9% in 2012-2013 . These findings are consistent with recent findings from a national registry reporting that only 1 in 5 patients with myocardial infarction were discharged with high-intensity statins. 23, 24 Of Medicare beneficiaries who were discharged from a hospital after an acute myocardial infarction, only 27% of patients' first prescription after discharge was for a high-intensity statin. 25 Factors noted to be associated with reduced uptake of appropriate highintensity statin use include a focus on low-density lipoprotein cholesterol goals and patient concerns regarding adverse effects. 25 The suboptimal use of intensive statin therapy among 21.9 million US adults in 2012-2013 with established ASCVD raises concerns about missed opportunities for intensive secondary prevention in high-risk patients and highlights an important opportunity to improve care and reduce recommended treatment gaps. While statin use is a commonly used quality metric to assess optimal care of patients with ASCVD, 26 it is necessary to also include dose intensity as a quality metric to maximize the myriad benefits of statin therapy in highrisk patients. Increased education is needed to have physicians prescribe recommended statin doses to high-risk patients independent of low-density lipoprotein cholesterol levels. Inequalities in high-value treatment gaps have generated significant interest in recent years from investigators and policy makers. Previous cross-sectional studies have suggested widespread inequities in statin use among select demographic groups. 20, 27, 28 We expand on this work, showing that while statin use among younger patients; women; racial/ethnic minorities, especially black and Hispanic individuals; and the uninsured have improved over time, practice gaps persisted over the 12-year study period. Although disparities in insurance coverage have been identified by the Institute of Medicine as a key driver of persistent health care discrepancies among these vulnerable groups, our findings demonstrate differential uptake of statins among different demographics groups not fully explained by insurance characteristics. This suggests that Our comprehensive analysis of trends in total statin drug costs for the US adult population provides valuable insights for policy makers with regard to projecting the cost of cardiovascular care. Our data show that the introduction of generic statins had a pronounced effect on the cost associated with statin use in the last 12 years. Over the study period, the gross domestic product-adjusted cost for statins went from $17.2 billion in 2002-2003, peaking at $22 billion in 2008-2009 , followed by a downward trend to $16.9 billion in 2012-2013. Over the same period, patient cost-share for statins decreased from 44.2% ($7.6 billion) to 23.1% ($3.9 billion), with the mean annual OOP cost per user reduced by 75% from $348 to $94. While the reduction in costs since 2008-2009 is encouraging, further gains can be achieved by expanding the use of generic statins. With most major statins coming off patent during the study period, an increase in generic statin use was noted. In the general population, brand-name statin use decreased from 91.6% to 18.2% over the study period. Similar reductions were noted among all study subgroups (eFigure 2 in the Supplement). All statins that became generic saw increases in their prescription, reflecting appropriate clinician market response (eFigure 3 in the Supplement). However, despite these impressive reductions, 1 in 5 patients in 2013 continued to take brand-name statins despite equivalent generic alternatives, blunting additional potential cost reductions. Therapeutic substitution from brand-name to generic statins, which is influenced by the preferences of physicians and/or patients, is of paramount importance in the current climate of cost-containment.
Limitations
The present findings should be interpreted in the context of the following limitations. First, because the MEPS was carried out in a noninstitutionalized adult population, our results are only generalizable to adults dwelling in communities and not those living in nursing homes. Second, our classification of adults into ASCVD risk groups was partly based on self-report, which could result in possible underestimation of risk groups' sizes. Third, any statin use was considered regardless of the number of prescriptions to ensure accurate estimation of expenditures and this could potentially overestimate statin use. However, when statin use was considered to be restricted to individuals with at least 2 prescriptions, it did not affect the results, but we observed lesser statin use as we increased the threshold for the number of prescriptions in our description of statin use. Of note, when limited to 2 or more prescriptions, the proportion of the population using statins was 22.4%, and it was 20.0% when limited to 3 or more prescriptions. It is important to note that our results do not reflect patterns of adherence and long-term use. Finally, our study lacked insight into the status of statin use following the adoption of the American College of Cardiology/American Heart Association guidelines in 2013 as the MEPS Prescribed Medicine File was not released at the time of the current study. However, previous goaldirected guidelines would necessitate high-intensity statin use in most high-risk patients regardless.
Conclusions
In conclusion, while use of statins has increased substantially in the general population from 2002 to 2013, appropriate uptake in high-risk groups remains suboptimal, with persistent disparities noted among women, racial/ethnic minorities, and the uninsured. We noted that high-intensity statin use remains an important gap that needs to be more aggressively targeted by policy makers. Although significant temporal reduction in drug costs continues to be realized with broader generic substitution, in 2013, almost 1 in 5 prescriptions were branded and accounted for 55% of total statin-related expenditures. These findings have important public health implications and should stimulate further discussions among stakeholders for pragmatic patient-centered interventions to improve appropriate statin use and manage associated costs. 
eAppendix. Methods
Medical Expenditure Panel Survey Prescribed Medicine Data Collection and Accuracy
The Medical Expenditure Pane Survey (MEPS) is a nationally representative source of data on healthcare resource utilization and expenditures sponsored by the Agency for Healthcare
Research and Quality (AHRQ). MEPS comprises of the Household Components (HC) and the
Medical Provider Component (MPC). Information on prescription medications were mostly
collected from individuals and families during the household surveys, and other information were obtained from dispensing pharmacy.
Data Collection Procedure
At each HC interview, the household respondent supplies information on any prescribed medicine that family members obtained as part of a visit to an inpatient stay, emergency room, hospital outpatient clinic or dentist's office and subsequently filled. The details supplied include the drug name, number of times it was obtained, the health condition it was prescribed for, the year and month it was first used, and whether free samples of the drug were received. Some payment information was obtained during the HC interview. This includes the third-party payer and the amount paid out-of-pocket.
Respondents were then asked to identify the names, addresses, and types of pharmacies that filled each prescriptions, along with permission for MEPS to contact the pharmacies and acquire data from them. Signed authorizations allow pharmacies to respond to the Pharmacy Component (PC) of MEPS, which is a subset of the MPC. In 2011, for example, 69.7% of HC respondents granted permission to contact pharmacies, and 73.3% of pharmacies responded 1 . The PC collects detailed information via telephone, fax, or mail from the pharmacies about the drugs obtained, including payments (the sum of which is the price), payers, date each prescription was filled, quantity dispensed, the National Drug Code (NDC), and precise drug attributes. The reason for the PC is to collect information that pharmacies can more easily and accurately provide than household respondents, since some HC respondents lack adequate documentations about payments (especially when third party payers are involved), and they may also lack detailed knowledge of their medications, such as the number or strength of pills.
Handling Missing Data
Occasionally, even for respondents who granted written permission for MEPS to contact their supplying pharmacy, some information is missing and must be imputed. If the NDC is imputed and the quantity is missing, then the quantity is taken from the same acquisition that donated the NDC. Otherwise, matching software imputes a quantity from another acquisition. Match variables include the NDC; active ingredients, dosage form, and strength; and characteristics of the person reported in the HC (age, sex, health conditions, and health status). Exact matching on the drug is required, and heavier weight is placed on the NDC, followed by the dosage form and strength. In the 2011 data, the quantity dispensed was imputed for 0.7 percent of the 252,176 acquisition. If the pharmacy does not provide the NDC, the PC asks instead for the medication name, dosage form, strength, strength unit. With that, the drug can be characterized.
When the pharmacy does not identify a third-party payer, information from the HC about insurance coverage and usual third-party payer can usually indicate the type of payer. Other missing pharmacy expenditure information for a person's drug are imputed from the pharmacy data for another person's purchase of similar drug 2 . Even when payment data appear to be complete, MEPS attempts to detect inaccurate payment data by comparing an acquisition's price to a price provided in the Wolters Kluwer's Master Drug Data Base (MDDB).
Accuracy of Prescribed Medicine Data
In 44.1 (37.9-50.4) 46.9 (40.5-53.4) 42.2 (35.7-48.9) 57.8 (51.9-63.5) 56.2 (50.8-61.5) 54.3 (48.0-60.6) High Income (≥400% of FPL) 41.4 (34.7-48.5) 53.8 (46.8-60.7) 53.9 (47.4-60.2) 
